BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14684291)

  • 1. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Jan; 14(1):29-32. PubMed ID: 14684291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly potent PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Jan; 14(1):207-10. PubMed ID: 14684329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally active PDE4 inhibitor with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Eur J Med Chem; 2004 Jul; 39(7):555-71. PubMed ID: 15236836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
    Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
    Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.
    Guay D; Hamel P; Blouin M; Brideau C; Chan CC; Chauret N; Ducharme Y; Huang Z; Girard M; Jones TR; Laliberté F; Masson P; McAuliffe M; Piechuta H; Silva J; Young RN; Girard Y
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1457-61. PubMed ID: 12031319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.
    Ochiai H; Odagaki Y; Ohtani T; Ishida A; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Kobayashi K; Nakai H; Toda M
    Bioorg Med Chem; 2004 Oct; 12(19):5063-78. PubMed ID: 15351390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
    Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
    J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
    Côté B; Frenette R; Prescott S; Blouin M; Brideau C; Ducharme Y; Friesen RW; Laliberté F; Masson P; Styhler A; Girard Y
    Bioorg Med Chem Lett; 2003 Feb; 13(4):741-4. PubMed ID: 12639571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted furans as inhibitors of the PDE4 enzyme.
    Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
    Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE4 inhibitors: new xanthine analogues.
    Montana JG; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Miotla J; Morris K; Naylor R; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2925-30. PubMed ID: 9873649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
    Macdonald D; Perrier H; Liu S; Laliberté F; Rasori R; Robichaud A; Masson P; Huang Z
    J Med Chem; 2000 Oct; 43(21):3820-3. PubMed ID: 11052785
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
    Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
    J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.